Midcap pharma regains its vigour on Dalal Avenue

0
11


Mumbai: Midcap pharma shares are on a tear as traders guess on defensive shares which are extra attractively supplied and have sturdy earnings progress prospects within the close to to medium time period.

Nectar Lifesciences resulted in 20 per cent higher circuit whereas Morepen Laboratories, Marksans Pharma gained over 19 per cent every. Suven Life Sciences, Novartis India, Poly Medicure, Panacea Biotech, AstraZeneca India, Shilpa Medicare, Hikal, Lincoln Pharma, SPARC,



Source link

HostGator Web Hosting

LEAVE A REPLY

Please enter your comment!
Please enter your name here